Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Neoplasms 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Proteus Syndrome 1Ovarian Neoplasms 1Lymphoma 1Hereditary Sensory and Autonomic Neuropathies 1Growth Disorders 1Congenital Abnormalities 1

Interventions

Fulvestrant 9Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3Cetuximab 3sapanisertib 2pembrolizumab 2parsaclisib 2binimetinib 2Topotecan 2NVP-BKM120 2Irinotecan 2Gemcitabine 2venetoclax 1tipifarnib 1talazoparib 1sotorasib 1ruxolitinib 1olaparib 1obinutuzumab 1niraparib 1lorlatinib 1liposomal doxorubicin 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hereditary Sensory and Autonomic Neuropathies × Miransertib × Clear all
NCT03317366 2021-08-06

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

No longer available

Congenital Abnormalities, Growth Disorders, Hereditary Sensory and Autonomic Neuropathies, Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡